Analysts Issue Forecasts for RNAC FY2025 Earnings

Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Cartesian Therapeutics in a research report issued to clients and investors on Monday, March 17th. Cantor Fitzgerald analyst K. Kluska expects that the company will post earnings per share of ($3.65) for the year. Cantor Fitzgerald currently has a "Hold" rating on the stock. The consensus estimate for Cartesian Therapeutics' current full-year earnings is $4.56 per share.

Other equities analysts have also recently issued reports about the company. BTIG Research initiated coverage on Cartesian Therapeutics in a report on Thursday, December 19th. They issued a "buy" rating and a $42.00 target price on the stock. HC Wainwright reduced their price target on Cartesian Therapeutics from $45.00 to $40.00 and set a "buy" rating for the company in a research report on Friday, March 14th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $41.00 price objective on shares of Cartesian Therapeutics in a research report on Thursday, March 13th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Cartesian Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $42.14.

Cartesian Therapeutics Stock Up 0.8 %

RNAC traded up $0.12 during trading on Wednesday, hitting $16.05. The company's stock had a trading volume of 125,425 shares, compared to its average volume of 114,188. The business's 50 day simple moving average is $18.39 and its 200-day simple moving average is $18.77. The firm has a market cap of $415.81 million, a PE ratio of -0.30 and a beta of 0.71. Cartesian Therapeutics has a one year low of $11.67 and a one year high of $41.87.

Remove Ads

Insider Buying and Selling

In other news, CTO Metin Kurtoglu sold 2,458 shares of Cartesian Therapeutics stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $16.83, for a total transaction of $41,368.14. Following the sale, the chief technology officer now owns 62,258 shares in the company, valued at $1,047,802.14. This trade represents a 3.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Blaine Davis sold 4,028 shares of the company's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $16.83, for a total transaction of $67,791.24. Following the transaction, the chief financial officer now owns 94,811 shares of the company's stock, valued at approximately $1,595,669.13. This represents a 4.08 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 14,744 shares of company stock valued at $247,337. Corporate insiders own 57.90% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets boosted its stake in Cartesian Therapeutics by 122.5% during the third quarter. BNP Paribas Financial Markets now owns 1,651 shares of the company's stock valued at $27,000 after buying an additional 909 shares during the last quarter. Virtus ETF Advisers LLC bought a new position in shares of Cartesian Therapeutics during the 4th quarter valued at approximately $63,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Cartesian Therapeutics by 22.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,562 shares of the company's stock valued at $82,000 after purchasing an additional 847 shares in the last quarter. Wells Fargo & Company MN raised its stake in Cartesian Therapeutics by 112.7% during the fourth quarter. Wells Fargo & Company MN now owns 4,847 shares of the company's stock valued at $87,000 after purchasing an additional 2,568 shares in the last quarter. Finally, Corebridge Financial Inc. raised its stake in Cartesian Therapeutics by 32.6% during the fourth quarter. Corebridge Financial Inc. now owns 5,122 shares of the company's stock valued at $92,000 after purchasing an additional 1,258 shares in the last quarter. Hedge funds and other institutional investors own 86.95% of the company's stock.

About Cartesian Therapeutics

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.